The Endometrial Receptivity Analysis (ERA) is a genetic test that tries to identify the precise window when your womb lining is ready to accept an embryo. It is one of the most talked-about IVF “add-ons” — and one of the most oversold. The honest summary is this: for most people having their first or second transfer, the best trials show ERA does not improve the chance of a baby, and it may even delay success. Its possible value is limited to a small group with genuinely repeated, unexplained failure, and even there the evidence is debated.
What is the implantation window?
After ovulation — or after progesterone is started in a frozen transfer cycle — the lining of the womb (the endometrium) goes through a short period of receptivity. Only during these roughly two days does the lining express the right pattern of genes and surface molecules to let an embryo attach and burrow in. Reproductive medicine calls this the “window of implantation.”
In a natural or standard IVF cycle, this window is timed by the calendar: transfer is planned for a set number of days after ovulation or after progesterone begins, because for the large majority of women the window falls where we expect it. The ERA test starts from a simple, reasonable question — what if, in a small number of people, that window is shifted earlier or later than the standard timing assumes?
What the ERA test actually measures
ERA does not look at embryos, egg quality or hormones in your blood. It looks only at the endometrium itself. A laboratory examines the activity of a panel of genes in a small sample of lining tissue and compares your pattern against reference profiles. It then classifies the sample as:
- Receptive — the lining was in its implantation window at the moment it was sampled, so standard timing suits you.
- Pre-receptive — the window had not opened yet, suggesting the embryo should be placed later (more hours of progesterone).
- Post-receptive — the window had already passed, suggesting the embryo should be placed earlier.
When the result is not “receptive,” the idea is to shift the timing of a future transfer by the number of hours the test suggests — so-called “personalised embryo transfer.”
How the biopsy cycle works
The important practical point is that ERA needs its own dedicated cycle — you cannot test and transfer at the same time. The sequence is:
- You run a full mock cycle that copies your planned transfer exactly — the same oestrogen preparation, then progesterone started on the same schedule.
- On the day a transfer would normally happen, instead of placing an embryo, a small sample of endometrial lining is taken in the clinic. The biopsy itself takes moments and feels like a brief, strong period cramp; no anaesthetic is usually needed.
- The sample is sent to the laboratory, and results take one to a few weeks.
- Only in a later cycle is the embryo transferred, using the timing the test recommended.
So choosing ERA means adding at least one extra month, one extra medicated cycle and one extra procedure before your embryo is ever transferred. That cost — in time, money and emotional energy — matters when we weigh whether it is worthwhile.
The honest evidence: routine use is not supported
This is where careful, evidence-based practice parts company with clinics that market the test to everyone. The largest and best-designed study to date — a randomised controlled trial in good-prognosis patients — compared personalised transfer guided by ERA against standard-timing transfer. It found no improvement in the ongoing pregnancy or live-birth rate from using ERA. Later analyses and systematic reviews have reached the same conclusion for unselected patients, and some data raise the possibility that acting on a “non-receptive” result could occasionally move the timing in the wrong direction and lower success.
Because of this, major bodies are cautious. ESHRE and other guideline groups classify endometrial receptivity testing as an add-on that should not be offered routinely, and the HFEA, which rates IVF add-ons by evidence, does not endorse it for general use. The reproductive-medicine consensus is straightforward: for a first transfer of a good embryo, ERA is not recommended.
Who might genuinely benefit?
The remaining, honest question is whether a much smaller group benefits. ERA is sometimes considered for people with recurrent implantation failure — several transfers of good-quality embryos that have not implanted despite everything else looking right. The reasoning is that if the common causes have been excluded, a shifted implantation window becomes a more plausible explanation worth testing for.
Even here, though, the evidence is genuinely debated rather than settled. Some centres report that a subset of these patients do have a displaced window and go on to conceive after personalised timing; other studies find no clear advantage. The truthful position is that ERA in recurrent implantation failure is a reasonable option to discuss, not a proven cure — and it should sit alongside a full assessment of embryo quality, the uterine cavity, and other factors. If you are in this situation, our companion guide on recurrent IVF failure walks through the wider work-up that should come first.
How we approach add-ons at UCARER
Our view is that a fertility clinic earns trust by recommending only what the evidence supports — and by saying plainly when something is unproven, even if it could be sold. We will not add ERA, or any other test, to a first transfer simply because it is available. Where a treatment genuinely fits your history, we explain the honest odds; where it does not, we say so. That principle runs through everything from our transfer planning to our choice of fresh versus frozen transfer and our overall IVF approach.
A note on treatment scope: donor eggs, donor sperm and donor embryos are not permitted in Turkey. Our clinic provides own-egg and own-sperm IVF and ICSI, and if your physician believes own-gamete treatment is unlikely to succeed, you will be told honestly rather than sold repeated cycles.
If an embryo has not implanted, it is almost never a reflection of anything you did or failed to do. Implantation is complex biology, and much of it remains outside our control. The right response is a calm, evidence-based review — not a rush toward every add-on on the menu.
Sources: ESHRE, HFEA, WHO and accepted reproductive-medicine guidance. This article is for general education and does not replace a medical consultation. Reviewed by Assist. Prof. Dr. Muzaffer Uçarer (Obstetrics & Gynaecology · IVF and Reproductive Medicine), UCARER Women’s Health, Istanbul.
